帕尼单抗治疗转移性结直肠癌II期试验中肿瘤演变的动态分子分析与临床相关性
该研究基于帕尼单抗联合伊立替康治疗转移性结直肠癌的II期试验,采用下一代测序和BEAMing分析治疗前后肿瘤组织及血浆游离DNA中RAS突变的发生。血浆BEAMing检测的突变RAS出现率为36.7%,高于肿瘤组织的9.5%(NGS)和6.3%(BEAMing)。探索性分析显示,进展时出现RAS突变的患者与保持野生型者的中位无进展生存期相似。
要点
- 血浆游离DNA BEAMing检测RAS突变出现率36.7%,高于肿瘤组织检测。
- 血浆RAS突变首次检测中位早于进展3.6个月(范围-0.3至7.5个月)。
- 进展时出现RAS突变者与野生型者的中位无进展生存期相似。
核心结论
- 在转移性结直肠癌中,连续血浆活检比肿瘤组织活检更能全面评估肿瘤异质性,但血浆检测的临床效用尚待进一步探索。
研究设计与样本
- 基于帕尼单抗联合伊立替康治疗转移性结直肠癌的II期试验,分析治疗前后存档肿瘤组织活检样本及治疗前、中、后采集的血浆样本,采用下一代测序和BEAMing检测RAS突变。
主要发现
- 肿瘤组织RAS突变出现率:下一代测序为9.5%(n=21),BEAMing为6.3%(n=16)。
- 血浆游离DNA BEAMing检测的突变RAS出现率为36.7%(n=39)。
- 血浆探索性分析显示,进展时出现RAS突变的患者与进展时保持野生型的患者中位无进展生存期相似。
- 连续血浆分析显示,首次检测到RAS突变出现中位早于进展3.6个月(范围-0.3至7.5个月)。
- 未发现可预测近期结局的突变RAS等位基因频率阈值。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. MATERIALS AND METHODS: Archival pre- and post-treatment tumor biopsy samples from a phase II study of panitumumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) that also collected plasma samples before, during, and after treatment were analyzed for emergence of mutations during/post-treatment by next-generation sequencing and BEAMing. RESULTS: The rate of emergence of tumor tissue RAS mutations was 9.5% by next-generation sequencing (n = 21) and 6.3% by BEAMing (n = 16). Plasma testing of cell-free DNA by BEAMing revealed a mutant RAS emergence rate of 36.7% (n = 39). Exploratory outcomes analysis of plasma samples indicated that patients who had emergent RAS mutations at progression had similar median progression-free survival to those patients who remained wild-type at progression. Serial analysis of plasma samples showed that the first detected emergence of RAS mutations preceded progression by a median of 3.6 months (range, -0.3 to 7.5 months) and that there did not appear to be a mutant RAS allele frequency threshold that could predict near-term outcomes. CONCLUSIONS: This first prospective analysis in mCRC showed that serial plasma biopsies are more inclusive than tissue biopsies for evaluating global tumor heterogeneity; however, the clinical utility of plasma testing in mCRC remains to be further explored. CLINICALTRIALS.GOV IDENTIFIER: NCT00891930.
引用
- Siena S, Sartore-Bianchi A, Garcia-Carbonero R, et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol. 2018. PMID: 28945848. doi:10.1093/annonc/mdx504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。